Lung function parameters in omalizumab responder patients: An interesting tool?

F PaganinG MangiapanA ProustA PrudhommeJ AttiaS Marchand-AdamF PelletF MilheB MelloniA BernadyC RaspaudC NocentP BergerLaurent Guilleminault

Published in: Allergy (2017)

After omalizumab initiation, FEV1 improved at 6 months in responder patients and then remained stable for 2 years. RV and RV/TLC improved at 6 months.

Keyphrases

end stage renal disease
lung function
newly diagnosed
ejection fraction
mycobacterium tuberculosis
chronic kidney disease
prognostic factors
chronic obstructive pulmonary disease
cystic fibrosis
air pollution